Table 1. Characteristics of studies included.
| Author, Year [Reference No.] | Groups, N | Age | Male, n (%) | NEWS2 score D1 | Hospitalization, requiring supplemental oxygen D1, n (%) | Hospitalization, requiring HFNC or non-invasive mechanical ventilation D1, n (%) | Time to clinical improvement (d) | Clinical improvement by D28, n (%) | Mortality, n (%) | Serious adverse events, n (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cao, 2020 [17] | 20 Ruxolitinib group | 63 (51 - 65) | 12 (60.0%) | 5 (4 - 7) | 18 (90.0%) | 2 (10.0%) | 12 (10 - 19) | 18 (90.0%) | 0 (0.0%) | 0 |
| 21 SOC group | 64 (59 - 71) | 12 (57.1%) | 4 (4 - 5) | 18 (85.7%) | 3 (14.3%) | 15 (10 - 18) | 18 (85.7%) | 3 (14.3%) | 4 | ||
| 2 | Giudice, 2020 [16] | 7 Ruxolitinib group | 61 (53 - 70) | 6 (86%) | - | 5 (71.4%) | 1 (14.3%) | 24 (16 - 44) | 3 (42.9%) | 1 (14.3%) | 1 |
| 10 SOC group | 63.5 (31 - 85) | 7 (70.0%) | - | 3 (30.0%) | 1 (10.0%) | 34 (9 - 60) | NA | 1 (10.0%) | 4 | ||
| 3 | Rosée, 2020 [5] | 14 Ruxolitinib sub-group | 66 (55 - 81) | 11 (79.0%) | 8.5 (4 - 16) | 2 (14.0%) | 11 (79.0%) | 18 (9 - 36) | 10 (71.4%) | 1 (7.1%) | - |
| 105 SOC group | - | 47 (44.8%) | - | - | - | - | 66 (63.0%) | 12 (11%) | - | ||
| 4 | Koschmieder, 2020 [19] | 1 Ruxolitinib group | 55 | 1 (100.0%) | - | 1 (100.0%) | - | 15 | 1 (100.0%) | 0 (0.0%) | - |
| 5 | Saraceni, 2020 [18] | 1 Ruxolitinib group | 59 | 1 (100.0%) | - | - | 1 (100.0%) | 45 | 0 (0.0%) | 0 (0.0%) | - |
| 6 | Portsmore, 2020 [20] | 1 Ruxolitinib group | 74 | 0 | - | - | 1 (100.0%) | 28 | 1 (100.0%) | 0 (0.0%) | - |
| 1 Ruxolitinib group | 54 | 1 (100.0%) | - | - | 1 (100.0%) | 64 | 0 (0.0%) | 0 (0.0%) | - | ||
| 7 | Innes, 2020 [21] | 1 Ruxolinitib group | 53 | 1 (100.0%) | - | - | 1 (100.0%) | 28 | 1 (100.0%) | 0 (0.0%) | - |
Values are presented as median interquartile range-unless otherwise specified.
Days of hospitalization, median interquartile range 18.
NEWS2, The National Early Warning Score 2; D1, day 1; SOC, standard of care; HFNC, high-flow nasal cannula; D1, day 1; D28, day 28; NA, non-applicable.